SAN CARLOS, Calif., April 21, 2023 (GLOBE NEWSWIRE) — Vaxcyte, Inc. PCVX, an innovative, clinical-stage vaccines company developing high-fidelity vaccines to protect humanity from the effects of bacterial disease, today announced the closing of its previously announced underwritten public offering of 13,030,000 common shares at a public offering price of $41.00 per share known prefunded warrants to purchase 1,000,000 common shares at a public offering price of $40,999 per underlying share. This includes the full exercise of the underwriters’ option to purchase up to 1,830,000 additional common shares at the public offering price per share, less subscription discounts and commissions. Total gross proceeds to Vaxcyte from this offering were approximately US$575 million, before deducting underwriting rebates and commissions and other offering costs payable by Vaxcyte.

BofA Securities, Jefferies, SVB Securities, Evercore ISI and Guggenheim Securities acted as joint book-running managers for the offering. Cantor acted as lead manager for the bid. Needham & Company and BTIG acted as co-managers for the offering.

A shelf registration statement relating to the securities being offered has been filed with the Securities and Exchange Commission (SEC) and was effective automatically upon filing on July 2, 2021. A final prospectus supplement and an accompanying prospectus relating to the offering have been filed with the SEC and are available on the SEC’s website, located at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to this offering may be obtained from BofA Securities NC1-022-02-25, Attention: Prospectus Department, 201 North Tryon Street, Charlotte, North Carolina 28255-0001 or by email at dg .prospectus_requests@bofa.com; Jefferies LLC, Attention: Equity Syndicate Department, 520 Madison Avenue, New York, New York 10022, by phone at 1-877-821-7388 or by email…